These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784 [TBL] [Abstract][Full Text] [Related]
3. Veno-occlusive disease/sinusoidal obstruction syndrome after haematopoietic stem cell transplantation: Middle East/North Africa regional consensus on prevention, diagnosis and management. Al Jefri AH; Abujazar H; Al-Ahmari A; Al Rawas A; Al Zahrani Z; Alhejazi A; Bekadja MA; Ibrahim A; Lahoucine M; Ousia S; Bazarbachi A Bone Marrow Transplant; 2017 Apr; 52(4):588-591. PubMed ID: 27892944 [TBL] [Abstract][Full Text] [Related]
4. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ; Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079 [TBL] [Abstract][Full Text] [Related]
5. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children. Qureshi A; Marshall L; Lancaster D Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502 [TBL] [Abstract][Full Text] [Related]
6. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. Corbacioglu S; Richardson PG Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848 [TBL] [Abstract][Full Text] [Related]
9. Defibrotide for the management of sinusoidal obstruction syndrome in patients who undergo haemopoietic stem cell transplantation. Coutsouvelis J; Avery S; Dooley M; Kirkpatrick C; Spencer A Cancer Treat Rev; 2016 Nov; 50():200-204. PubMed ID: 27721142 [TBL] [Abstract][Full Text] [Related]
16. A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Corbacioglu S; Topaloglu O; Aggarwal S Clin Drug Investig; 2022 Jun; 42(6):465-476. PubMed ID: 35594010 [TBL] [Abstract][Full Text] [Related]
17. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation. Pichler H; Horner K; Engstler G; Poetschger U; Glogova E; Karlhuber S; Martin M; Eibler W; Witt V; Holter W; Matthes-Martin S Biol Blood Marrow Transplant; 2017 Jul; 23(7):1128-1133. PubMed ID: 28359910 [TBL] [Abstract][Full Text] [Related]
19. Defibrotide: An Oligonucleotide for Sinusoidal Obstruction Syndrome. Aziz MT; Kakadiya PP; Kush SM; Weigel K; Lowe DK Ann Pharmacother; 2018 Feb; 52(2):166-174. PubMed ID: 28914546 [TBL] [Abstract][Full Text] [Related]